美国食品和药物管理局批准诺沃克的Optune Lua设备用于治疗晚期非小细胞肺癌. FDA approves Novocure's Optune Lua device for treating advanced non-small cell lung cancer.

美国食品和药物管理局批准了诺沃奇的Optune Lua设备用于治疗非小细胞肺癌. The FDA has approved Novocure's Optune Lua device for treating non-small cell lung cancer. 该便携式装置发射电场以干扰癌症细胞分部,用于接受化疗后癌症发病的病人。 This portable device emits electric fields to disrupt cancer cell division and is intended for patients whose cancer has advanced after chemotherapy. 临床试验表明,与标准疗法相比,用户的死亡风险减少了26%。 Clinical trials indicated a 26% reduced risk of death for users compared to standard therapies. 批准可能会改善Novocure的财务状况,因为该公司报告收入损失巨大。 The approval may improve Novocure's financial situation, as the company reported significant revenue losses.